ARID1A and cancer: The survival analysis of ARID1Amut vs. ARID1Awt tumors across TCGA pan-cancer studies and MSK-IMPACT cohorts queried in cBioPortal website (40), generated partially discordant results, and specifically favorable prognosis is reported for ARID1A mutant TCGA cohort (q-value<0.001 for progression-free and disease-free survival, q-value 0.1 for overall survival) and a negative prognosis (p-value 0.007) for the MSK cohort.